Jazz Pharmaceuticals
JAZZ
305 hedge funds and large institutions have $7.51B invested in Jazz Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 117 increasing their positions, 108 reducing their positions, and 55 closing their positions.
7% more capital invested
Capital invested by funds: $7.03B → $7.51B (+$474M)
8% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 108
4% less funds holding
Funds holding: 318 → 305 (-13)
8% less funds holding in top 10
Funds holding in top 10: 13 → 12 (-1)
18% less call options, than puts
Call options by funds: $107M | Put options by funds: $130M
22% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$214M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$57.5M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$53.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$51M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$43.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$60.9M |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$45.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$44.2M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$43.1M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$40M |
JAZZ Hedge Fund Activity: Q2 2014 in Review
305 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2014, worth a combined $7.51B — up 6.7% from $7.03B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of JAZZ and 43 opened new positions — a net loss of 12 holders — while 108 trimmed existing stakes and 117 added.
The largest buyer was Putnam Investments, adding an estimated $214M. The largest seller was T. Rowe Price Associates, cutting an estimated $60.9M.
- 305 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2014, down from 318 in Q1 2014.
- Funds reported $7.51B of Jazz Pharmaceuticals stock for Q2 2014, up 6.7% quarter-over-quarter.
- 43 funds opened new Jazz Pharmaceuticals positions in Q2 2014 and 55 closed out, a net change of -12 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2014 was Putnam Investments, an estimated $214M added.
- The largest Jazz Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $60.9M sold.
Based on aggregated 13F filings for Q2 2014.